Drag a card by its title · ⚙ to size, swap or remove

The company

Arvinas, Inc.

ARVN · Nasdaq

Health CareBiotechnologyNot moving yet

ARVN stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 28 weeks. It is 12.8% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 28
Industry in uptrend: 18% -9 in 4 wk
Insider buys, 12 months: $536K
Insider sales, 12 months: $2.8M
Officials’ trades on record: 0
Institutions holding: 193 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

23 Apr – 22 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months19

Buyers · sellers1 · 6

Who	Did	Shares	Traded
Andrew SaikChief Financial Officer	sold	5,696at $8.16	24 Jun 2026filed 24 Jun 2026
Angela M. CacaceChief Scientific Officer	sold	2,576at $7.60	17 Jun 2026filed 18 Jun 2026
Randy TeelPresident and CEO	sold	2,209at $9.04	21 May 2026filed 22 May 2026
Randy TeelPresident and CEO	sold	9,657at $9.94	11 May 2026filed 13 May 2026
Noah BerkowitzChief Medical Officer	sold	11,108at $9.94	11 May 2026filed 13 May 2026
Angela M. CacaceChief Scientific Officer	sold	9,657at $9.94	11 May 2026filed 13 May 2026
David K. LoomisVP, Chief Accounting Officer	sold	1,919at $9.94	11 May 2026filed 13 May 2026
Andrew SaikChief Financial Officer	sold	11,139at $9.94	11 May 2026filed 13 May 2026
Noah BerkowitzChief Medical Officer	sold	6,435at $11.10	18 Mar 2026filed 19 Mar 2026
Briggs MorrisonDirector	bought	20,000at $13.40	6 Mar 2026filed 9 Mar 2026
John G. HoustonDirector	sold	4,688at $13.24	27 Feb 2026filed 2 Mar 2026
John G. HoustonDirector	sold	18,822at $13.24	27 Feb 2026filed 2 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders193-3 on the quarter

New · exited37 · 40

Reported value$457.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.added · filed 7 Aug 2026	7,609,123$63.2M	+811,539+11.9%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026	4,123,399$34.3M	+233,771+6.0%
D. E. Shaw & Co., Inc.reduced · filed 14 Aug 2026	3,495,153$29.0M	-143,414−3.9%
Pfizer Incunchanged · filed 13 Aug 2026	3,457,815$27.7M	00.0%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 2026	2,796,000$23.2M	+818,000+41.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	2,714,163$22.6M	+24,801+0.9%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026	2,573,447$21.4M	+741,333+40.5%
STATE STREET CORPadded · filed 7 Aug 2026	2,196,872$18.3M	+368,400+20.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	1,667,265$13.9M	+110,158+7.1%
Qube Research & Technologies Ltdadded · filed 14 Aug 2026	1,592,276$13.2M	+390,641+32.5%